Clinical Trials · NCT00131469

Study of Teriparatide (FORTEO) to Treat Adults With Osteogenesis Imperfecta

CompletedPhase 4Teriparatide (Approved)
Phase
Phase 4
Recruitment status
Completed
Sponsor
Oregon Health and Science University
Enrollment
79
Start date
Jun 2005
Locations
3 sites, United States
Primary endpoint
Spine Bone Mineral Density (BMD)
View Teriparatide compound reference